• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗保险部分 D 人群中全面和非全面药物审查导致的积极药物变化。

Positive Medication Changes Resulting from Comprehensive and Noncomprehensive Medication Reviews in a Medicare Part D Population.

机构信息

1 University of Arizona Medication Management Center, Tucson, Arizona.

2 University of Arizona College of Pharmacy, Tucson, Arizona.

出版信息

J Manag Care Spec Pharm. 2017 Mar;23(3):388-394. doi: 10.18553/jmcp.2017.23.3.388.

DOI:10.18553/jmcp.2017.23.3.388
PMID:28230451
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10397760/
Abstract

BACKGROUND

Health care organizations face the challenge of reducing costs while improving health outcomes. Currently, more than 39 million seniors are enrolled in a Medicare Part D prescription benefit plan, many of whom also qualify for medication therapy management (MTM) services. MTM programs provide valuable services designed to prevent or resolve medication-related problems (MRPs). Two core components of all MTM programs include comprehensive medication reviews (CMRs) with followup interventions and focused non-CMR interventions. Currently, there is limited research comparing the rate of MRPs resolved by CMR and non-CMR interventions.

OBJECTIVE

To determine whether CMRs versus non-CMR interventions resulted in more pharmacist-initiated intervention recommendations and positive medication changes.

METHODS

This retrospective, cross-sectional quality improvement project evaluated outcomes for individuals who received interventions following a CMR compared with those who received non-CMR interventions as part of a comprehensive MTM program. For this project, eligible individuals qualified for an MTM program. A positive medication change was defined as the addition of an appropriate medication or the removal of an inappropriate medication within 120 days of a pharmacist recommendation. Differences between the groups were calculated using the Wilcoxon rank sum test.

RESULTS

During the 2-year period (2012 and 2013), 788,756 beneficiaries were enrolled in the MTM program and evaluated for potential MRPs. In both years, pharmacists recommended more medication changes per member for those receiving a CMR (0.81 in 2012 and 0.82 in 2013) compared with the non-CMR group (0.68 in 2012 and 0.61 in 2013; P value < 0.001 for both years). However, recommendations made via non-CMR interventions (representing the vast majority of all medication reviews) were more likely to result in a positive medication change (OR = 1.24, 95% CI = 1.21-1.28 for 2012; OR = 1.26, 95% CI = 1.22-1.30 for 2013).

CONCLUSIONS

These quality improvement project results suggest that Medicare Part D beneficiaries participating in a university-based MTM program who received non-CMR interventions had a higher likelihood of having positive medication changes than those receiving CMRs. These results are enlightening and may provide initial evidence to support inclusion of a non-CMR performance metric for the Centers for Medicare & Medicaid Service's star ratings for MTM programs.

DISCLOSURES

No outside funding supported this study. The University of Arizona Medication Management Center (UAMMC)/SinfoniaRx provides grant funding to the University of Arizona for research. Augustine reports support from the UAMMC and ownership of Pfizer stock and was a graduate student at the University of Arizona College of Pharmacy at the time of this study. The authors report no other potential conflicts of interest. Buhl and Augustine contributed study concept and design, collected the data, and wrote the manuscript. Data interpretation was performed by all the authors. Taylor, Warholak, Augustine, and Martin revised the manuscript.

摘要

背景

医疗保健组织面临着在提高医疗效果的同时降低成本的挑战。目前,有超过 3900 万老年人参加了医疗保险部分 D 处方福利计划,其中许多人也有资格获得药物治疗管理 (MTM) 服务。MTM 计划提供了有价值的服务,旨在预防或解决药物相关问题 (MRPs)。所有 MTM 计划的两个核心组成部分包括全面药物审查 (CMR) 及其后续干预措施和重点非 CMR 干预措施。目前,关于 CMR 和非 CMR 干预措施解决 MRPs 的速度的研究有限。

目的

确定 CMR 与非 CMR 干预措施相比,是否会导致更多的药剂师发起干预建议和积极的药物改变。

方法

这项回顾性、横断面质量改进项目评估了接受 CMR 后接受干预的个体与作为综合 MTM 计划一部分接受非 CMR 干预的个体的结果。对于这个项目,符合条件的个体有资格参加 MTM 计划。一个积极的药物改变被定义为在药剂师建议后的 120 天内添加适当的药物或去除不适当的药物。使用 Wilcoxon 秩和检验计算两组之间的差异。

结果

在 2012 年和 2013 年的两年期间,有 788756 名受益人为参加 MTM 计划并评估潜在的 MRPs。在这两年中,接受 CMR 的患者每个成员的药物变化建议更多(2012 年为 0.81,2013 年为 0.82),而非 CMR 组(2012 年为 0.68,2013 年为 0.61;两个年份的 P 值均<0.001)。然而,通过非 CMR 干预措施(代表所有药物审查的绝大多数)做出的建议更有可能导致积极的药物变化(2012 年的比值比 [OR] = 1.24,95%置信区间 [CI] = 1.21-1.28;2013 年的 OR = 1.26,95% CI = 1.22-1.30)。

结论

这些质量改进项目的结果表明,参加基于大学的 MTM 计划的医疗保险 D 部分受益人为参与非 CMR 干预措施的人比接受 CMR 的人更有可能有积极的药物变化。这些结果具有启发性,可能为支持医疗保险和医疗补助服务中心的 MTM 计划星级评定纳入非 CMR 绩效指标提供初步证据。

披露

没有外部资金支持这项研究。亚利桑那大学药物管理中心 (UAMMC)/SinfoniaRx 为亚利桑那大学的研究提供赠款资金。奥古斯丁报告说他从 UAMMC 获得支持并拥有辉瑞的股票,并且在这项研究进行时他是亚利桑那大学药学院的研究生。作者报告没有其他潜在的利益冲突。Buhl 和奥古斯丁提出了研究概念和设计,收集了数据,并撰写了手稿。所有作者都进行了数据解释。Taylor、Warholak、奥古斯丁和 Martin 对稿件进行了修订。

相似文献

1
Positive Medication Changes Resulting from Comprehensive and Noncomprehensive Medication Reviews in a Medicare Part D Population.医疗保险部分 D 人群中全面和非全面药物审查导致的积极药物变化。
J Manag Care Spec Pharm. 2017 Mar;23(3):388-394. doi: 10.18553/jmcp.2017.23.3.388.
2
Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.使用标准化招募脚本提高综合药物审查接受率:一项随机对照试验。
J Manag Care Spec Pharm. 2017 Jan;23(1):13-21. doi: 10.18553/jmcp.2017.23.1.13.
3
Comparison of Medication Therapy Management Services and Their Effects on Health Care Utilization and Medication Adherence.药物治疗管理服务的比较及其对医疗保健利用和药物依从性的影响。
J Manag Care Spec Pharm. 2019 Jun;25(6):688-695. doi: 10.18553/jmcp.2019.25.6.688.
4
Comprehensive Medication Reviews in Long-term Care Facilities: History of Process Implementation and 2015 Results.长期护理机构的综合药物评估:实施过程的历史和 2015 年的结果。
J Manag Care Spec Pharm. 2017 Jan;23(1):22-26. doi: 10.18553/jmcp.2017.23.1.22.
5
Evaluation of Comprehensive Medication Review Completion Rates Using 3 Patient Outreach Models.使用 3 种患者外展模型评估综合药物审查完成率。
J Manag Care Spec Pharm. 2016 Jul;22(7):796-800. doi: 10.18553/jmcp.2016.22.7.796.
6
Medication Therapy Management: 10 Years of Experience in a Large Integrated Health Care System.药物治疗管理:在大型综合性医疗保健系统中的 10 年经验。
J Manag Care Spec Pharm. 2020 Sep;26(9):1057-1066. doi: 10.18553/jmcp.2020.26.9.1057.
7
Cost-effectiveness of comprehensive medication reviews versus noncomprehensive medication review interventions and subsequent successful medication changes in a Medicare Part D population.医疗保险部分 D 人群中综合药物审查与非综合药物审查干预措施的成本效益,以及随后成功的药物改变。
J Manag Care Spec Pharm. 2015 May;21(5):381-9. doi: 10.18553/jmcp.2015.21.5.381.
8
Effect of an Advanced Pharmacy Practice Experience on Medication Therapy Management Services in a Centralized Retail Pharmacy Program.进阶药学实践经验对集中式零售药房计划中药物治疗管理服务的影响。
J Manag Care Spec Pharm. 2017 May;23(5):561-565. doi: 10.18553/jmcp.2017.23.5.561.
9
Evaluation of prescriber responses to pharmacist recommendations communicated by fax in a medication therapy management program (MTMP).在药物治疗管理项目(MTMP)中,评估处方医生对通过传真传达的药剂师建议的反应。
J Manag Care Pharm. 2011 Jun;17(5):345-54. doi: 10.18553/jmcp.2011.17.5.345.
10
Associations Between Chronic Disease, Polypharmacy, and Medication-Related Problems Among Medicare Beneficiaries.医疗保险受益人与慢性病、多种药物治疗和药物相关问题之间的关联。
J Manag Care Spec Pharm. 2019 May;25(5):573-577. doi: 10.18553/jmcp.2019.25.5.573.

引用本文的文献

1
Implementing Clinical Decision Support Tools and Pharmacovigilance to Reduce the Use of Potentially Harmful Medications and Health Care Costs in Adults With Heart Failure.实施临床决策支持工具和药物警戒以减少心力衰竭成人患者潜在有害药物的使用并降低医疗保健成本。
Front Pharmacol. 2021 Apr 30;12:612941. doi: 10.3389/fphar.2021.612941. eCollection 2021.
2
Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present.医疗保险D部分药物治疗管理计划从2006年设立至今的演变历程。
Am Health Drug Benefits. 2019 Sep;12(5):243-251.
3
Patterns and predictors of older adult Medicare Part D beneficiaries' receipt of medication therapy management.老年医疗保险D部分受益人的药物治疗管理接受模式及预测因素
Res Social Adm Pharm. 2020 Sep;16(9):1208-1214. doi: 10.1016/j.sapharm.2019.12.007. Epub 2019 Dec 9.
4
Assessing the Effect of a Telepharmacist's Recommendations During an Integrated, Interprofessional Telehealth Appointment and Their Alignment with Quality Measures.评估电话药师在综合、跨专业远程医疗预约期间的建议效果及其与质量措施的一致性。
J Manag Care Spec Pharm. 2019 Dec;25(12):1334-1339. doi: 10.18553/jmcp.2019.25.12.1334.
5
Comparison of Medication Therapy Management Services and Their Effects on Health Care Utilization and Medication Adherence.药物治疗管理服务的比较及其对医疗保健利用和药物依从性的影响。
J Manag Care Spec Pharm. 2019 Jun;25(6):688-695. doi: 10.18553/jmcp.2019.25.6.688.
6
Associations Between Chronic Disease, Polypharmacy, and Medication-Related Problems Among Medicare Beneficiaries.医疗保险受益人与慢性病、多种药物治疗和药物相关问题之间的关联。
J Manag Care Spec Pharm. 2019 May;25(5):573-577. doi: 10.18553/jmcp.2019.25.5.573.
7
The Effect of Plan Type and Comprehensive Medication Reviews on High-Risk Medication Use.计划类型和综合药物审查对高风险药物使用的影响。
J Manag Care Spec Pharm. 2018 May;24(5):416-422. doi: 10.18553/jmcp.2018.24.5.416.

本文引用的文献

1
Identifying the Optimal Role for Pharmacists in Care Transitions: A Systematic Review.确定药剂师在护理转接中的最佳角色:一项系统评价。
J Manag Care Spec Pharm. 2015 Aug;21(8):614-36. doi: 10.18553/jmcp.2015.21.8.614.
2
Cost-effectiveness of comprehensive medication reviews versus noncomprehensive medication review interventions and subsequent successful medication changes in a Medicare Part D population.医疗保险部分 D 人群中综合药物审查与非综合药物审查干预措施的成本效益,以及随后成功的药物改变。
J Manag Care Spec Pharm. 2015 May;21(5):381-9. doi: 10.18553/jmcp.2015.21.5.381.
3
Discrepancies identified with the use of prescription claims and diagnostic billing data following a comprehensive medication review.在全面药物审查后,使用处方索赔和诊断计费数据时发现的差异。
J Manag Care Pharm. 2014 Feb;20(2):165-73. doi: 10.18553/jmcp.2014.20.2.165.
4
Evaluation of medication therapy management services for patients with cardiovascular disease in a self-insured employer health plan.在一个自保雇主健康计划中对心血管疾病患者的药物治疗管理服务进行评估。
J Manag Care Pharm. 2013 Jun;19(5):385-95. doi: 10.18553/jmcp.2013.19.5.385.
5
An employer-based, pharmacist intervention model for patients with type 2 diabetes.基于雇主的、针对 2 型糖尿病患者的药剂师干预模式。
Am J Health Syst Pharm. 2010 Feb 15;67(4):312-6. doi: 10.2146/ajhp090047.
6
Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years.社区药房7年期间药剂师提供的药物治疗管理(MTM)服务分析
J Manag Care Pharm. 2009 Jan-Feb;15(1):18-31. doi: 10.18553/jmcp.2009.15.1.18.
7
Clinical and economic outcomes of medication therapy management services: the Minnesota experience.药物治疗管理服务的临床与经济结果:明尼苏达的经验
J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):203-214. doi: 10.1331/JAPhA.2008.07108.
8
Reconcilable differences: correcting medication errors at hospital admission and discharge.可调和的差异:纠正住院和出院时的用药错误
Qual Saf Health Care. 2006 Apr;15(2):122-6. doi: 10.1136/qshc.2005.015347.
9
Drug-therapy problems, inconsistencies and omissions identified during a medication reconciliation and seamless care service.在用药核对与无缝护理服务过程中发现的药物治疗问题、不一致之处及遗漏情况。
Healthc Q. 2005;8 Spec No:65-72. doi: 10.12927/hcq..17667.
10
Medication reconciliation in acute care: ensuring an accurate drug regimen on admission and discharge.急性护理中的用药核对:确保入院和出院时药物治疗方案准确无误。
Jt Comm J Qual Patient Saf. 2005 Jul;31(7):406-13. doi: 10.1016/s1553-7250(05)31054-3.